COVID-19 treatments earned 4 drugmakers $14B in 2021

Monoclonal antibody therapies and antivirals to treat COVID-19 collectively earned Eli Lilly, Gilead Sciences, Merck, and Regeneron Pharmaceuticals more than $14 billion in 2021, MarketWatch reported Feb. 4.

Here is what each of the drugmakers made in sales from their COVID-19 treatments last year, based off year-end earnings reports cited by MarketWatch.